Non-surgical treatment after immunotherapy for specific gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether patients with advanced gastric cancer (a specific type called dMMR/MSI-H) can be treated without surgery after receiving immunotherapy and chemotherapy. The goal is to see if this approach can control the cancer while avoiding the risks of surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with advanced gastric cancer of a specific type (dMMR/MSI-H)
- Your cancer has not spread widely to other organs or invaded surrounding tissues
- You do not have another active cancer elsewhere in your body
- Your other organs (heart, lungs, liver, kidneys) are working well enough to tolerate treatment
- You are willing to participate and follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy before surgery can help people with a specific type of stomach cancer (dMMR/MSI-H) that can be removed. It aims to see how well the immune system responds and if the tumor shrinks.
This trial tests combining an immunotherapy drug (sintilimab) with low-dose radiation before surgery for stomach cancer that has a specific genetic marker (dMMR/MSI-H). The goal is to see if this combination can shrink the tumor and improve outcomes without needing strong chemo.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial is for people with certain types of gastrointestinal cancers that have a genetic feature called MSI-H/dMMR or POLE mutation. It looks at whether, after immunotherapy, you can avoid surgery or have a less invasive procedure instead, such as watching and waiting, endoscopic removal, or limited surgery.
This trial tests a combination of short-course radiation, standard chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with advanced or metastatic gastric cancer that hasn't spread to lymph nodes. The goal is to see if this approach can help shrink or control the tumor.
Hear when a new Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.